Welcome to our dedicated page for OmniAb SEC filings (Ticker: OABI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OmniAb, Inc. filings document the public-company disclosures of an antibody discovery technology business that licenses its platform to pharmaceutical, biotechnology and academic partners. Its Form 8-K reports furnish operating and financial results, partner program updates, guidance-related disclosures and other material events tied to the company’s licensing, service, milestone and royalty model.
The company’s proxy and governance filings cover annual meeting matters, director elections, auditor ratification, shareholder voting results and bylaw amendments addressing proxy-solicitation procedures and stockholder proposal mechanics. OmniAb filings also identify its emerging growth company status, Nasdaq-listed common stock and warrants, and recurring capital-structure and governance disclosure topics.
OmniAb, Inc. will hold its 2026 Annual Meeting of Shareholders on June 17, 2026 at 8:00 a.m. Pacific Time in Emeryville, California. Shareholders of record as of April 23, 2026 will vote on electing two Class I directors and ratifying Ernst & Young LLP as auditor for 2026.
The proxy highlights a seven-member board with an independent chair, fully independent key committees, and restrictions on insider trading, pledging and hedging. It details executive pay, with CEO Matthew Foehr’s 2025 package combining salary, cash bonus and stock-based incentives tied to strategic, technology, portfolio, financial, and culture goals.
OmniAb, Inc. director Philip J. Gotwals reported an exercise of restricted stock units into common shares. On April 21, 2026, 13,333 Restricted Stock Units converted into 13,333 shares of Common Stock at a stated price of $0.0000 per share.
Following the transaction, he directly holds 13,333 shares of Common Stock and 46,667 Restricted Stock Units. The RSUs vest in three substantially equal annual installments beginning April 21, 2026, subject to his continued service with OmniAb through each vesting date.
OmniAb, Inc. director Steven C. Crouse acquired 13,333 shares of Common Stock through the exercise of Restricted Stock Units at a stated price of $0.00 per share. Following the transaction, he directly holds 13,333 Common shares and 46,667 Restricted Stock Units.
The 13,333 Restricted Stock Units referenced in the filing vest in three substantially equal annual installments beginning on April 21, 2026, subject to Crouse’s continued service. Each Restricted Stock Unit represents a contingent right to receive one share of OmniAb’s Common Stock.
The issuer reported a Form 144 notice for the proposed sale of 13,542 shares of Common Stock classified as Restricted Stock and labeled Compensation. The filing lists two prior sales in February: 6,828 and 9,301 shares.
OmniAb, Inc. President and CEO Matthew W. Foehr reported routine equity compensation activity. On April 7, 2026, 36,459 Restricted Stock Units vested and were converted into the same number of OmniAb common shares at no exercise price. To satisfy tax withholding obligations tied to this vesting, 19,244 shares of common stock were sold in mandated “sell-to-cover” transactions at a weighted average price of $1.49 per share, rather than at Foehr’s discretion. Following these transactions, Foehr directly holds 4,420,492 shares of OmniAb common stock and 309,376 RSUs, indicating that the sale represents a small portion of his overall equity position.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice for proposed sale of 36,459 shares of restricted common stock on 04/07/2026, listed as compensation securities. The filing also records prior sales of 20,754 shares on 02/17/2026 and 30,843 shares on 02/18/2026.
OmniAb, Inc. Executive VP, Finance and CFO Kurt A. Gustafson reported routine equity compensation activity. On April 7, 2026, 13,542 Restricted Stock Units vested, converting into the same number of common shares at no cost. To cover tax withholding on this vesting, 6,913 common shares were sold in a mandated sell-to-cover transaction at a weighted average price of $1.49 per share, rather than as a discretionary sale. After these events, he directly holds 261,483 shares of OmniAb common stock, reflecting prior transfers including 13,997 shares delivered to an ex-spouse under a domestic relations order.
OmniAb, Inc. Chief Legal Officer Charles S. Berkman reported routine equity compensation activity. On April 7, 2026, 13,542 Restricted Stock Units vested, converting into the same number of common shares at no exercise price. To satisfy tax withholding obligations under OmniAb’s equity incentive plans, 7,157 common shares were sold in a mandated “sell-to-cover” transaction at a weighted-average price of $1.49 per share, rather than as a discretionary trade. Following these transactions, Berkman directly holds 399,085 shares of OmniAb common stock and 111,042 RSUs, indicating that only a small portion of his position was sold.
OABI filed a Rule 144 notice to sell 13,542 shares of common stock. The filing lists these as restricted stock issued for compensation with an intended sale date of 04/07/2026. The notice also reports prior sales of 6,990 shares on 02/17/2026 and 9,673 shares on 02/18/2026.
OmniAb, Inc. provides a licensing-based antibody discovery platform used by pharmaceutical, biotech and academic partners to develop next‑generation therapeutics. Its transgenic animal technologies, AI‑driven screening and ion channel expertise are designed to generate fully human, high‑quality antibody candidates across many disease areas.
OmniAb’s business model centers on platform access fees, research services, milestones and downstream royalties on partner products. As of December 31, 2025, the company reported 107 active partners and 407 active programs, including 27 clinical programs, two antibodies under regulatory review and three approved, partner‑commercialized products.